Solara Active Pharma Sciences announced its Q3FY26 financial results, reporting revenue of ₹349 crores alongside a consolidated net loss of ₹17.43 crores. The pharmaceutical company's Board of Directors approved the unaudited financial results for the quarter ended December 31, 2025, during their meeting held on February 6, 2026.

Financial Performance Overview

The company's Q3FY26 results demonstrate revenue growth compared to the corresponding quarter of the previous year, with total income reaching ₹349 crores against ₹301.80 crores in Q3FY25. However, the company recorded a consolidated net loss of ₹17.43 crores, marking a significant shift from the ₹8.09 crores profit achieved in the same quarter last year.

Exceptional Charges Impact Operations

A significant factor affecting the quarter's performance was exceptional charges of ₹6.75 crores related to gratuity and compensated absences impact under new labour codes. This one-time charge substantially impacted the company's profitability metrics for the quarter. Before exceptional items, the company reported a loss of ₹10.68 crores compared to a profit of ₹8.09 crores in the corresponding quarter last year.

Nine-Month Performance Analysis

For the nine months ended December 31, 2025, Solara Active Pharma Sciences reported total income of ₹983.16 crores compared to ₹1,013.12 crores in the corresponding period last year. The company recorded a consolidated net loss of ₹17.01 crores for the nine-month period, contrasting with a profit of ₹2.64 crores in the previous year.

Rights Issue and Financial Position

The company continues its rights issue program, having raised ₹311.85 crores out of the total ₹449.95 crores rights issue as of December 31, 2025. This includes ₹157.48 crores from application money and ₹154.37 crores from the first call, with ₹134.99 crores pending from the final call. The company maintains accumulated losses of ₹329.64 crores as of December 31, 2025, with net current liabilities exceeding current assets by ₹92.44 crores.

Strategic Developments and Outlook

Solara Active Pharma Sciences operates primarily in the Active Pharmaceutical Ingredient segment. The Board of Directors had previously approved exploring the demerger of CRAMS and Polymers business into an independent listed entity, leading to the incorporation of wholly owned subsidiary Synthix Global Pharma Solutions Limited on April 29, 2025. The company expects to continue operations on a going concern basis, anticipating adequate cash flows from operations and working capital facility renewals.

Veritas Finance Limited announced its unaudited financial results for the quarter ended December 31, 2025, demonstrating strong operational performance across key financial metrics. The Chennai-based non-banking financial company (NBFC) reported robust growth in both revenue and profitability during the third quarter of fiscal year 2026.

Financial Performance Highlights

The company's financial results showcase consistent growth momentum with total income from operations reaching significant levels during the reporting period.

Nine-Month Performance

For the nine-month period ended December 31, 2025, Veritas Finance demonstrated sustained growth across all major financial parameters.

Capital Structure and Key Ratios

The company maintains a stable capital structure with paid-up equity share capital of ₹13,136.42 lakhs as of December 31, 2025. Net worth stood at ₹3,00,448.02 lakhs, while total capital and outstanding debt reached ₹6,59,604.19 lakhs. The debt equity ratio was recorded at 2.20 for the quarter.

Earnings Per Share Performance

Veritas Finance reported earnings per share of ₹6.23 for the quarter ended December 31, 2025, compared to ₹5.15 in the previous quarter and ₹5.25 in the corresponding quarter of the previous year. For the nine-month period, EPS reached ₹16.08.

Business Operations

Veritas Finance Limited operates as an NBFC registered with the Reserve Bank of India and is classified under the middle layer as per scale-based regulations. The company focuses on extending credit to micro and small enterprises, self-employed businesses, and the salaried segment for business expansion, working capital, house construction, and purchase of used commercial vehicles. The company's debt securities are listed on both BSE and NSE.

Regulatory Compliance

The financial results were prepared in accordance with Indian Accounting Standards (Ind AS) 34 for interim financial reporting and have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on February 4, 2026. The results have also been subjected to limited review by the company's statutory auditors.